Femasys announces financial results for year ended december 31, 2024, and provides corporate update

-- company expands commercial product offering with fembloc ® permanent birth control (delivery system) approval in europe and signed partnerships for distribution in spain -- atlanta, march 27, 2025 (globe newswire) -- femasys inc. (nasdaq: femy), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended december 31, 2024 and provides a corporate update.
FEMY Ratings Summary
FEMY Quant Ranking